• Login
    • Login
    Advanced Search
    View Item 
    •   UoN Digital Repository Home
    • Journal Articles
    • Faculty of Science & Technology (FST)
    • View Item
    •   UoN Digital Repository Home
    • Journal Articles
    • Faculty of Science & Technology (FST)
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900

    Thumbnail
    View/Open
    Abstract.pdf (55.58Kb)
    Date
    2012
    Author
    Gönen, M
    Sun, Z
    Figueroa, ME
    Patel, JP
    Abdel-Wahab, O
    Racevskis, J
    Ketterling, RP
    Fernandez, H
    Rowe, JM
    Tallman, MS
    Melnick, A
    Levine, RL
    Paietta, E
    Type
    Article
    Language
    en
    Metadata
    Show full item record

    Abstract
    We determined the prognostic relevance of CD25 (IL-2 receptor-α) expression in 657 patients (≤ 60 years) with de novo acute myeloid leukemia (AML) treated in the Eastern Cooperative Oncology Group trial, E1900. We identified CD25(POS) myeloblasts in 87 patients (13%), of whom 92% had intermediate-risk cytogenetics. CD25 expression correlated with expression of stem cell antigen CD123. In multivariate analysis, controlled for prognostic baseline characteristics and daunorubicin dose, CD25(POS) patients had inferior complete remission rates (P = .0005) and overall survival (P < .0001) compared with CD25(NEG) cases. In a subset of 396 patients, we integrated CD25 expression with somatic mutation status to determine whether CD25 impacted outcome independent of prognostic mutations. CD25 was positively correlated with internal tandem duplications in FLT3 (FLT3-ITD), DNMT3A, and NPM1 mutations. The adverse prognostic impact of FLT3-ITD(POS) AML was restricted to CD25(POS) patients. CD25 expression improved AML prognostication independent of integrated, cytogenetic and mutational data, such that it reallocated 11% of patients with intermediate-risk disease to the unfavorable-risk group. Gene expression analysis revealed that CD25(POS) status correlated with the expression of previously reported leukemia stem cell signatures. We conclude that CD25(POS) status provides prognostic relevance in AML independent of known biomarkers and is correlated with stem cell gene-expression signatures associated with adverse outcome in AML.
    URI
    http://www.ncbi.nlm.nih.gov/pubmed/22855599
    http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/57960
    Publisher
    College of Biological and Physical Sciences ,Department of physics
    Collections
    • Faculty of Science & Technology (FST) [4266]

    Copyright © 2022 
    University of Nairobi Library
    Contact Us | Send Feedback

     

     

    Useful Links
    UON HomeLibrary HomeKLISC

    Browse

    All of UoN Digital RepositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Copyright © 2022 
    University of Nairobi Library
    Contact Us | Send Feedback